Gabelli Funds LLC Raises Stake in ICU Medical, Inc. $ICUI

Gabelli Funds LLC increased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 8.5% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 76,500 shares of the medical instruments supplier’s stock after purchasing an additional 6,000 shares during the quarter. Gabelli Funds LLC owned 0.31% of ICU Medical worth $10,109,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. EP Wealth Advisors LLC purchased a new position in shares of ICU Medical in the 1st quarter valued at $479,000. Vident Advisory LLC purchased a new stake in ICU Medical during the 1st quarter worth $270,000. Simon Quick Advisors LLC acquired a new stake in ICU Medical in the 2nd quarter valued at $275,000. Woodline Partners LP increased its holdings in ICU Medical by 31.6% in the 1st quarter. Woodline Partners LP now owns 160,910 shares of the medical instruments supplier’s stock valued at $22,344,000 after purchasing an additional 38,671 shares in the last quarter. Finally, AlphaQuest LLC raised its position in ICU Medical by 3,058.3% in the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after purchasing an additional 1,468 shares during the period. 96.10% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ICUI shares. Wall Street Zen downgraded ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Piper Sandler raised their target price on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. Finally, KeyCorp upped their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus price target of $181.75.

ICU Medical Stock Up 0.9%

Shares of NASDAQ ICUI opened at $143.77 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $175.51. The stock’s 50-day simple moving average is $129.97 and its 200-day simple moving average is $128.88. The firm has a market cap of $3.55 billion, a price-to-earnings ratio of -463.76 and a beta of 0.82.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The firm had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. During the same quarter last year, the firm earned $1.59 EPS. ICU Medical’s quarterly revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, equities analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the transaction, the director directly owned 3,995 shares in the company, valued at $560,977.90. This represents a 24.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This represents a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.